Serum Glycoprotein Biomarkers for Early EAC and Barrett's Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current screening methodologies for esophageal adenocarcinoma (EAC) are ineffective due to sampling errors, variability in biopsy assessments, and late-stage diagnoses, leading to low survival rates and missed diagnoses in patients with Barrett's esophagus (BE), highlighting the need for improved diagnostic and monitoring methods.
Innovation Solution
Identification of serum glycoproteins with different glycosylation profiles in subjects with EAC, BE, and healthy individuals, allowing for the detection and monitoring of these conditions through differential glycosylation analysis in biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If endoscopic screening with biopsy is used to diagnose EAC, then tissue samples can be obtained for histological analysis, but sampling errors and variability in assessment lead to false positives and missed diagnoses
Solution Approach 1:
The patent replaces the mechanical/endoscopic biopsy system with a biochemical detection system using serum biomarkers. Instead of obtaining tissue samples through endoscopy and analyzing them histologically, the invention uses blood-based biomarker panels that can be analyzed through laboratory tests, eliminating the need for invasive procedures and subjective histological assessment.
Solution Approach 2:
The patent introduces serum biomarkers as an intermediary between the disease state and diagnostic detection. These biomarkers serve as mediators that reflect the presence and progression of EAC and BE in the bloodstream, allowing indirect but more reliable detection compared to direct tissue sampling which suffers from sampling errors.
2Productivity
If endoscopic screening programs are implemented, then some cases of EAC can be detected, but more than 80% of EACs are diagnosed without prior diagnosis of BE and many patients with BE remain undiagnosed
Solution Approach 1:
The patent performs preliminary detection of EAC and BE through serum biomarker analysis before clinical symptoms manifest or before endoscopic changes become apparent. By detecting disease presence through biomarkers in the blood, the system identifies patients who need further evaluation, preventing missed diagnoses that occur with conventional screening.
Solution Approach 2:
The patent creates a universal screening tool that can detect multiple conditions (EAC and BE) through a single blood test. The biomarker panel serves multiple functions: detecting BE, detecting EAC, assessing disease progression, and monitoring treatment response, replacing the need for multiple separate diagnostic procedures.
3Reliability
If aggressive treatment is applied to EAC patients, then disease progression can be addressed, but the 5-year survival rate remains low at 9-24% due to late-stage diagnosis
Solution Approach 1:
The patent enables preliminary detection of EAC at earlier stages through serum biomarker analysis, allowing intervention before the disease reaches advanced stages. By detecting disease presence through biomarkers rather than waiting for symptomatic presentation or late-stage endoscopic findings, treatment can be initiated earlier, improving survival outcomes.
Data Source
AI summary
Disclosed are biomarkers for Barrett's esophagus and esophageal adenocarcinoma, and uses thereof, such as in methods for detecting the presence, and monitoring progression, of Barrett's esophagus and esophageal adenocarcinoma. Also disclosed are methods for treating and methods of monitoring the treatment of Barrett's esophagus and esophageal adenocarcinoma, as well as kits and compositions for use in such methods.